Market Overview

A McDonald's Analyst On The Chain's Meatless Prospects

Share:
A McDonald's Analyst On The Chain's Meatless Prospects

It's the news that many Beyond Meat Inc (NASDAQ: BYND) investors have been waiting for: the company has finally announced a partnership with McDonald's Corp (NYSE: MCD). 

The Analyst 

Stephens analyst Will Slabaugh maintained an Overweight rating on McDonald’s with a $230 price target.

Why It Matters

McDonalds has said it will test the Beyond Meat-based burger in 28 restaurants in southwestern Ontario beginning Sept. 30. It's known as the P.L.T. —plant, lettuce and tomato.

Beyond Meat shares surged on the news, but Slabaugh said he's not sold on the announcement and does not see McDonalds fully jumping on board with Beyond Meat in the near-term.

"This is McDonald’s first plant-based product, and it comes after Burger King launched its Impossible Whopper in August," the analyst said in a Thursday note. (See his track record here.)

Stephens views the entry into the plant-based market positively, but does not expect a "full-blown" alternative beef rollout at Golden Arches restaurants in the U.S. in the near term.

The reason why is largely tied to the supply chain, Slabaugh said.  

"However, we view an alternative chicken product (nugget, tender, sandwich) in the U.S. as a more likely nation-wide launch in 2020/2021 in conjunction with its exclusive poultry provider, Tyson Foods, Inc. (NYSE: TSN), which we would view as more novel and a likely larger sales driver."

McDonald's shares were trading 0.28% higher at $213.20 in Friday's premarket session. 

Related Links

Beyond Meat Won't Be Entering The Japanese Market Yet

Subway Partners With Beyond Meat To Trial Beyond Meatball Sub

Latest Ratings for BYND

DateFirmActionFromTo
Dec 2019Initiates Coverage OnPerform
Nov 2019Initiates Coverage OnBuy
Nov 2019Initiates Coverage OnNeutral

View More Analyst Ratings for BYND
View the Latest Analyst Ratings

Posted-In: Stephens Will SlabaughAnalyst Color Price Target Reiteration Restaurants Analyst Ratings General Best of Benzinga

 

Related Articles (MCD + BYND)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AMRXRaymond JamesDowngrades
MDStifelUpgrades33.0
CATStandpoint ResearchDowngrades
LULUPiperJaffrayMaintains245.0
LULUWells FargoMaintains260.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Data